Two Japanese patients with stage G3b chronic kidney disease and impaired glucose metabolism after renal transplantation successfully treated with empagliflozin

• Published in: Renal replacement therapy 2020-11, Vol.6 (1), p.55-8, Article 55
• Main Authors: Miyazaki, Ryoichi, Miyagi, Kyoko, Yoshida, Misaki
• Format: Article
• Language: English
• Subjects: Abdomen; Anemia; Blood pressure; Blood tests; Body temperature; Cardiovascular disease; Cholesterol; Creatinine; Diabetes; Edema; Empagliflozin; Glucose; Heart; Hemodialysis; Hemoglobin; Kidney diseases; Laboratories; Low density lipoprotein; Medical prognosis; Metabolism; Patients; Proteins; Renal transplant recipient; Stage G3b chronic kidney disease; Steroids; Uric acid; Urinalysis; Urine
• ISSN: 2059-1381; 2059-1381
• DOI: 10.1186/s41100-020-00303-x

BackgroundRenal transplant recipients with chronic kidney disease (CKD) often develop abnormal glucose metabolism. Although recent studies have reported the protective effects of sodium-glucose transport protein 2 (SGLT2) inhibitors on the heart and kidneys, few have assessed their effect in renal transplant patients. Moreover, to our knowledge, there have been no studies on the effects of SGLT2 inhibitors in renal transplant recipients in Japan.Case presentationCase 1 was a 67-year-old male renal transplant recipient with post-transplant diabetes mellitus. He was administered empagliflozin 10 mg once a day for 9 months. Over time, his HbA1c levels decreased from 6.8 to 6.0%. Case 2 was a 56-year-old male renal transplant recipient with fatty liver disease. He was administered empagliflozin 10 mg once a day for 9 months. His ALT, γ-GTP, and LDL-cholesterol levels all decreased. In both patients, body weight and the urine albumin to creatinine ratio (UACR) decreased after empagliflozin administration, but there were no changes in the estimated glomerular filtration rate. No adverse events occurred in either case.ConclusionsAdministration of empagliflozin had favorable outcomes in two patients with stage G3b CKD and abnormal glucose metabolism after renal transplantation. Further studies will be required to clarify the efficacy and safety of SGLT2 inhibitors in a larger population of patients with similar medical conditions.